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Abstract
Background: Rapid scale-up of antiretroviral therapy (ART) in resource-limited settings is accompanied with an increasing
risk of HIV drug resistance (HIVDR), which in turn could compromise the performance of national ART rollout programme. In
order to sustain the effectiveness of ART in a resource-limited country like Cameroon, HIVDR early warning indicators (EWI)
may provide relevant corrective measures to support the control and therapeutic management of AIDS.
Methods: A retrospective study was conducted in 2010 among 40 ART sites (12 Approved Treatment Centers and 28
Management Units) distributed over the 10 regions of Cameroon. Five standardized EWIs were selected for the evaluation
using data from January through December, among which: (1) Good ARV prescribing practices: target=100%; (2) Patient
lost to follow-up: target #20%; (3) Patient retention on first line ART: target $70%; (4) On-time drug pick-up: target $90%;
(5) ARV drug supply continuity: target=100%. Analysis was performed using a Data Quality Assessment tool, following WHO
protocol.
Results: The number of sites attaining the required performance are: 90% (36/40) for EWI1, 20% (8/40) for EWI2; 20% (8/40)
for EWI3; 0% (0/37) for EWI4; and 45% (17/38) for EWI 5. ARV prescribing practices were in conformity with the national
guidelines in almost all the sites, whereas patient adherence to ART (EWI2, EWI3, and EWI4) was very low. A high rate of
patients was lost-to-follow-up and others failing first line ART before 12 months of initiation. Discontinuity in drug supply
observed in about half of the sites may negatively impact ARV prescription and patient adherence. These poor ART
performances may also be due to low number of trained staff and community disengagement.
Conclusions: The poor performance of the national ART programme, due to patient non-adherence and drug stock outs,
requires corrective measures to limit risks of HIVDR emergence in Cameroon.
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Introduction
With a general population estimated at 19,401,000 inhabitants
in 2010, Cameroon had close to 560,300 adults and children living
with HIV/AIDS, among which 249,341 were eligible to receive
highly active antiretroviral therapy (HAART) based on the World
Health Organisation (WHO) criteria for eligibility to treatment
(CD4,350 cells/mL) [1–3]. Already 35.6% (89,455) of patients
eligible for treatment were receiving antiretroviral therapy (ART)
in the 145 treatment centers [HIV Approved Treatment Centers
(ATC), and HIV Management Units (HMU)] nationwide [4–5].
Despite the effectiveness of HAART in reducing morbidity and
mortality associated with AIDS, the ongoing scale-up of antiret-
rovirals (ARV) is inevitably associated with a high risk of HIV drug
resistance (HIVDR) to ARVs commonly used in the country [6–
7]. Since such practices might compromise the performance of the
national ART programme, HIVDR surveillance and prevention
are of paramount importance [8–11].
Surveillance and prevention of HIVDR was launched in
Cameroon with three main components: (1) Evaluation of early
warning indicators (EWIs) for HIVDR; (2) Evaluation of the
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36777threshold of transmitted HIVDR; and (3) Monitoring of HIVDR
among patients on ART [5]. These efforts resulted into recent
studies conducted by Aghokeng et al. and Kouanfack et al., showing
evidence of low to moderate levels of transmitted and acquired
drug resistance in adults living with HIV/AIDS in Cameroon
[12,13]. More recently, Fokam et al. showed a low (4.9%) and very
high (90%) levels of pediatric HIVDR, respectively among
children naı ¨ve to ART and those failing first line treatment, with
a median time-to-treatment failure of ,2 years [14]. Despite the
increasing awareness in Cameroon about HIVDR, and the
development of cost-effective HIVDR genotyping assays by Yang
et al. and by Fokam et al., respectively in 2010 and 2011 [15–16],
these reference assays are still unaffordable to a great majority of
patients. Due to the known limited affordability to such reference
laboratory equipment (HIV viral load and HIVDR testing) [4],
WHO strongly recommends the prevention of HIVDR using
EWIs as the less costly and rapid intervening population-based
approach to support and sustain the efficacy of current treatment
guidelines [8,17]. To this effect, WHO proposes six strongly
recommended and two optional EWIs, among which countries are
advised to select at least 4 for their national HIVDR prevention
activities [17]. Based on the contextual feasibility, five strongly
recommended EWIs were chosen by Cameroon [5]:
N EWI1: ‘‘Good ARV prescribing practices’’ (Percentage of patients
initiated on an appropriate first line ARV drug regimen).
Numerator: Number of individuals initiating ART at the site
who are prescribed a standard or otherwise appropriate first-
line regimen during the selected time period. Denominator:
Number of individuals starting ART during the selected time
period. The acceptable target performance: 100%.
N EWI2:‘ ‘ Patient lost to follow-up’’ (Percentage of patient lost to
follow-up after 12 months of enrolment to ART). Numerator:
Number of individuals initiating ART in a selected time period
who were not seen at the clinic or pharmacy $90 days after
the date of their last missed appointment or drug pick-up that
occurred within their first 12-months of ART, and who are not
known to have transferred out or died. Denominator: Number
of individuals starting ART during a selected time period. The
acceptable target performance #20%.
N EWI3: ‘‘Patient retention on appropriate first line ART’’ (Percentage
of patient retention on appropriate first line ART after 12
month of treatment). Numerator: Number of individuals
initiating first-line ART during a selected period of time who
are, 12 months from ART start, still on first-line ART (this
includes substitutions of one appropriate first-line regimen for
another, but not substitutions of dual- or monotherapy or a
inappropriate three-drug regimen). Denominator: Number of
individuals starting ART during a selected time period or, in
sites where data are available, that number minus the number
of individuals starting ART in that time period who transferred
out during the 12 months after starting ART. Individuals who
died, stopped ART, switched to second-line ART, or were lost
to follow-up must be included in the denominator. The
acceptable target performance $70%.
N EWI4: ‘‘On-time ARV drug pick-up’’ (Percentage of on-time ARV
drug pick-up by the patient). Numerator: number of
individuals who have picked up all their prescribed ARV
drugs on time during the selected time period. Denominator:
number of individuals classified as ‘‘on ARV drugs’’ during the
selected time period. The acceptable target performance
$90%.
N EWI5: ‘‘Drug supply continuity’’ (Percentage of ARV drug supply
continuity at the site pharmacy). Numerator: Number of
months or quarters in the year in which there were no ARV
drug stock outages for any ARVs in any of the standard ART
regimens supplied by the site or the pharmacy at which the
site’s patients pick up ARV drugs. Denominator: 12 months
(or 4 quarters). The acceptable target performance: 100%.
The objectives of our study is to evaluate the levels of these five
chosen HIVDR EWIs in ART sites all over Cameroon, in order to
identify potential strengths and weaknesses of the national ART
programme, and to inform the relevant evidence-based policies
necessary to improve the quality of clinical healthcare, the drug
supply/management system, and patient adherence; with the
ultimate goal of minimizing the development and the spread of
preventable HIVDR in the country.
Methods
Study Design
A descriptive, longitudinal and retrospective survey was
conducted in 2010 among 40 ART sites, 12 Approved Treatment
Centers (ATC) and 28 HIV Management Units (HMU),
distributed over the Cameroon national territory. The sample
size for EWI1 to EWI4 at each ART site was calculated based on
the WHO sampling method [5,17], a formula used to compare an
observed percentage to a theoretical percentage (threshold of
EWIs): N = (Z
26P6Q)/d
2; with N being the minimum sample
size, Z at an confidence interval of 95% (Z=1.96), P as the
expected percentage of retention on first line ART ($70%), Q as
1- P (30%), and D as the degree of accuracy (=7%). EWI5 was
calculated using the number of months in the year during which
there were no ARV drug stock outages for any ARVs in any of the
standard ART regimens.
Ethical clearance for the study was obtained from the
Cameroon National Ethics Committee (Authorization Nu034/
NEC/SE). Confidentiality was respected during abstraction of
data by the use of specific identification code for each enrolled
patient number. Since our study was conducted retrospectively,
data were collected from medical/ART and pharmacy registers
available at the ART sites. Thus, informed consent from the
participants was not required.
As per WHO-recommendations, heads of ART sites involved in
the survey and their respective data managers were preliminarily
trained on the relevance of HIVDR EWIs and on the
methodology for data collection and results interpretation. At
the level of each ART site, the five EWIs were collected using
WHO-standardized data collection forms. In detail, the first three
EWIs were obtained by abstraction of cumulative cohort data
from patient medical records/ART registers, while the two other
EWIs were abstracted from the pharmacy registers. A description
of each ART site was done, taking into consideration the level of
the HIV/AIDS clinic (ATC or HMU), the number of staff trained
and involved in the routine management of people living with
HIV. Data were collected among patients newly enrolled on ART
(starting from the month of January 2009, until completing the
required sample size) and followed-up throughout the first year of
ART, with an additional three months extension, necessary when
monitoring patients lost to follow-up at the ART site.
Data Validation, Analysis and Interpretation
Data validation was performed onsite using hard copies of
collected data and the ART registers; these data were then
centralized at the national level and entered into a standardized
HIV Drug Resistance Early Warning Indicators
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the hard data sheet was done at the central level to ensure
reliability and coherence. Validated data were then analyzed per
each site and then globally (nationwide), using a WHO routine
data quality assessment tool (RDQA) designed specifically for such
surveys. Results were automatically generated in the Excel spread
sheet.
An EWI attaining the acceptable or required target was
classified as ‘‘Good Performance’’, and any EWI unable to
reach the acceptable or required target was classified as ‘‘Poor
Performance’’.
Results
Description of the Surveyed Antiretroviral Therapy (ART)
Sites
All the sites selected for the survey in 2010 took part in the
study, giving a participatory rate of 100%. The geographical
distribution of the sites over the national territory suggests that the
results generated represent the overall national paradigm, as
shown in figure 1.
The national ART guidelines for the management of HIV
infection were available in all the surveyed sites. The protocols for
first line ARV drugs were also available and prescribed in all the
sites. However, protocols for second line ARV drugs were
prescribed only in the ATCs. In some of the study sites, ARV
drugs were provided at the main pharmacy or at an additional
pharmacy located within the health facility. Nevertheless, in all the
study sites, management of ARV drugs was done solely with stocks
forms, and most often by a pharmacy clerk. For a total of 55,646
patients on ART (among which 13,768 newly enrolled on ART) in
the 40 sites, an overall heavy workload (7/200 staff-to-patient
ratio) was found, and especially for the community relay agents
who were often less operational even when physically present (see
table 1).
The Level of Early Warning Indicators (EWI) in the Study
Sites
Data abstraction and validation was effective for EWI1, 2 and 3 in
all of the 40 sites. However, for EWI4, data from three sites were
not validated due to incoherence (Nkongsamba Regional Hospital,
‘‘Saint-Jean de Malte’’ hospital and Douala General Hospital, all
of the three sites belonging to the Littoral region of the country).
For EWI5, we recorded one not validated (Pete Regional Hospital
in the Far North region) and one unavailable data (Ede ´a District
Hospital in the Littoral region). Thus, in terms of data collection
and management, a unique region (Littoral region) was reported
with major weakness. The detailed site performance from EWI1 to
EWI5, grouped per region, is shown in table 2.
For a general evaluation of the national ART roll-out program
performance, data analysis of the overall national EWIs reported
only the prescribing practices closed to the target, as shown in
table 3.
For EWI1, a national performance of 90% (36 out of 40), with
the four failing sites having a performance of 99% (acceptable
target is 100%), implies that ARV drugs prescribing practices in
the country are in conformity with the current national ART
guidelines. Of note, the four sites with below targeted performance
were ATC (administering both first and second line ARV drugs),
thus dealing with a heavy workload and complexity in their clinical
routine activities. These sites belong to the centre, littoral and
western regions, which are regions with the highest number of
patients on treatment.
For EWI2, only 20% (8/40) of the sites were reported
with a rate of lost-to-follow-up below acceptable target of # 20%,
representing 33% (4/12) and 14% (4/28) of the ATC and the
HMU, respectively. This observation indicates a highrateof patient
lost-to-follow-up nationwide; with ATCs performing about twice as
well as HMUs. The poor performance ranged from 22% to 77%,
with the Ngaounde ´re ´ Lutheran Presbyterian hospital (Adamawa
region) and the Nkongsamba Regional Hospital (Littoral region)
showing the highest number of lost patients (77%), while the
Yaounde Gyneaco-Obstetric and Paediatric Hospital (Centre
region) and the Ede ´a District Hospital (East region) recorded the
lowest rates (4%, and 7% respectively). Furthermore, regional
comparison showed that the East region had the best performance
(Bertoua Regional Hospital, and Abong-Mbang District Hospital)
while the Adamawa Region had the lowest (Ngaounde ´re ´ Lutheran
Presbyterian Hospital). Therefore, there are several ART sites in
need of in-depth investigations to accurately highlight the outcome
of patient lost-to-follow-up (death, transfer, treatment interruption,
etc). These parameters are crucial to evaluate the real impact of this
indicator on patient compliance, as well as on the emergence and
transmission of HIVDR strains at the local and national level.
For EWI3, only 20% (8/40) of sites succeeded in retaining
patients on an appropriate first line ART following the acceptable
performance of $70%, amongst which 17% (2/12) and 21% (6/
28) were ATC and HMU, respectively. Therefore, there was a
similar performance between ATC and HMU in terms of
retaining patients on first line ART. However, sites with poor
performances varied from 62% (Bafoussam Regional Hospital)
to 19% (Ngaounde ´re ´ Lutheran Presbyterian Hospital). Further-
more, regional comparison revealed that the East region (all three
sites) had the best performance while the poorest resulted
from the Adamawa region (still the Ngaounde ´re ´ Lutheran
Presbyterian Hospital, as previously observed in EWI2). This
low rate of patient retention on first line may indicate an
important switch from first to second line drugs, potentially due
to a rapid spread of HIVDR within the geographical settings
concerned.
For EWI4, none of the sites reached the required target of
$90%, the rates obtained ranging from 0% at the Limbe
Regional Hospital to 73% at the Yaounde ´ Gyneco-Obstetric
and Paediatric Hospital. Comparison at the regional level showed
that the Centre region performed best (41.5%), while the Far
North region was the lowest (10%). Even though patient delay
could be explained by the availability of drugs on the appointment
day, these observations showed that the level of patient awareness
and/or adherence to ART is very low in all the study sites, possibly
requiring intensification or revision of adherence education,
implementation of policies to reduce the waiting time at the
pharmacy, a decrease in work load, or improved infrastructure.
For EWI5, only 45% of sites succeeded to ensure a 100%
performance in supplying drugs without interruption in any of the
ARV molecules. The 21 ART sites with poor performance
represented 100% (11/11) of the ATC and 37% (10/27) of HMU.
Thus, within the Cameroon context, ATC would be at three times
higher risk to run out of stock as compared to HMU. A
comparative regional performance showed that the Littoral was
the only region to reach the required target of 100%, while the
North-West region reported the lowest performance (27%),
remarkably with the Ndop District Hospital showing drug stock-
out every month. The national drug supply chain and/or the site
drug management system need to be revised, especially in ATUs
nationwide and in the North-West region of the country in
particular.
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e36777Figure 1. Geographical distribution of the 40 ART surveyed ART sites in 2010. The following referred to the 10 different geographical
regions in Cameroon: Adamaoua, Centre, Est, Extre ˆme-Nord, Littoral, Nord, Nord-Ouest, Ouest Sud, and Sud-Ouest. The other names referred to the
40 ART sites enrolled in this survey. ART: Antiretroviral therapy.
doi:10.1371/journal.pone.0036777.g001
Table 1. Staff/Patient ratio in the overall study population.
Health
Staff Medical Doctor Nurse Diagnostician
Pharmacist or
Pharmacy Clerk Counselor
Community
Relay Agent Data Manager
Staff/Patient ratio 1/267 1/74 1/434 1/694 1/434 1/323 1/1387
Staff (min-max) 0–25 0–153 0–25 0–9 0–12 0–8 1
doi:10.1371/journal.pone.0036777.t001
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An efficient evaluation of a national ART rollout programme in
resource-limited settings like Cameroon requires the design and
setting-up ‘‘easy-to-use’’, effective and affordable strategies for the
surveillance and prevention of HIVDR. More specifically, such
strategies are of great asset in a context where the commonly
available antiretrovirals used for patient management are of low
genetic barriers. Thus, preventing HIVDR through EWI surveys
may be useful in sustaining efforts to ensure the efficacy of the
commonly used ARV drugs, especially with the rapid scale-up
observed since 2003 after the ‘‘3 by 5’’ initiative and the ongoing
universal access to treatment [6–7]. The present study was
achieved due to the use of national standardized ART registers,
the training of clinicians and data managers, and site supervision.
However, the cases of discrepancies or incoherence of data
management observed in a few sites suggest the need for
continuous training of staff. Only an electronically standardized
data management system could enable an early identification and
correction of such incoherencies in data management, an activity
that may negatively impact the monitoring and evaluation strategy
toward a better control of HIVDR [5].
Our results show that good prescribing practices are performed
in the all the ART sites within the country health system. This
good performance would be likely due to the ongoing efforts in
training clinicians prescribing ARV drugs launched several years
ago. Importantly, patient initiation on ART is done by a
consortium agreement during a ‘‘treatment committee’’ (a weekly
meeting made-up of clinicians, nurses, pharmacists/pharmacy
clerks, biologists/laboratory technicians, counselors, and/or com-
munity relay agents, all trained and involved in patient follow-up)
at the ART site (ATC or HMU), an initiative which has greatly
contributed to the conformity of prescribing habits with national
guidelines. Therefore, an effective prevention of HIVDR goes
along with staff training on HIV/AIDS therapeutic management.
Our performance observed for EWI1 is consistent with those of
Hedt et al in Malawi and of Hong et al in Namibia [18–19], even
though the low sample size and incoherence in some of their data
have likely restricted the public health relevance of their findings.
Despite compliance with EWI1, the risk for HIVDR emerging
remains very high in the majority of the ART sites, as confirmed by
thehighrateof lost-to-follow-up, thelowrateofpatientretention on
first line ART after 12 months, and the alarming delay observed in
drug pick-up. Interestingly, ATCs performed about twice as well as
HMUs (33% of ATCs met EWI2 compared to 14% of HMUs),
suggesting that standard-meeting ATCs could mentor their
respective HMUs, by sharing positive experiences that help in
minimizing lost-to-follow-up. Evaluating the impact of the distance
between the patient’s residence and the ART site, the patient
educational level and compliance to ART, the impact of stigma on
adherence, as well as the length of waiting time spent by a patient
prior to medical consultation and/or reception at the pharmacy,
may help out to improve patient’s adherence to the ART rollout
program. It is obvious that, among patients lost to follow-up or on
treatment interruption, there is a high risk of developing HIVDR;
this isalsoanimportantfactorinthe transmission ofresistant species
in the community [17]. Also, even though ARV drugs are freely
offered to patients in Cameroon, the costs for medical consultation
and for laboratory analysis are potential limiting factors of patient
access to care, thereby increasing the probability of a patient to be
lost to follow-up. It is worth knowing that a patient lost to follow-up
is considered as a potential HIVDR carrier [5]. Thus, additional
resources and new community-based approaches may be needed to
reduce the rate of missing patients in the national ART program. In
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Hedt et al found a performance of 84% and 14%, respectively from
ART sites in the public and the private sector for EWI2 (required
target: #20%) [18–19]. Interestingly, our data also showed an
overall better performance for EWI2 in the public sector sites (23%,
8/35) as compared to the privates (0%, 0/5), thus suggesting that
the public sector likely has more appropriate resources or
approaches that increase target compliance. However, since a
similar approach is used nationwide for patient management and
follow-up, reducing the rate of patients lost to follow-up would
require more resources allocated in the private sector. Further
investigations may be needed for policy implementation.
The low rate of patient retention on first line ART after 12
months, reflecting a switch to a second line ART, may need to be
confirmed by a detailed evaluation of patients really in need of a
second line (through genotyping for HIV drug resistance testing).
Such investigation would be of great asset to manage and to prevent
early treatment failure, an ideal approach to limit the spread of
resistance to the limited options of ARVs available within the
national context, as it is the case in several resource-limited settings.
The impact of delay in drug pick-up may be better analyzed by pill
count, in order to effectively conclude on the real effect of the
observed delays on ART observance, since patient’s appointments
in several ATC and HMU are planned for 3 to 5 days before the
entire consumption of drugs. The heavy workload, expressed by the
staff-to-patients ratio (7/200), would have negatively affected the
performance of EWI 2, 3 and 4 (these three are indicators related to
ART adherence). With the creation of about a hundred new ART
sites in the coming years [20], decentralization or task shifting in
patient management (delineation of certain routine medical
activities to trained nurses) and an active community engagement,
would reduced the workload and the waiting time for patients,
would increased patient adherence, and would finally be of great
asset to control the development and spread of HIVDR [21].
The high rate of discontinuity in drug supply (observed in 55%
of the sites) would have increased poor adherence to the ART
programme, in terms of treatment interruption, lost to follow-up,
and delay in drug pick-up. Even though alternative therapeutic
options were generally provided during stock shutdown, a risk of
emerging HIVDR still remains. Difficulties related to ARV
continuous supply could be resolved by revising the drug supply
system/mechanism and by involving more trained staff in drug
procurement, or by decentralization in drug management.
Only a comprehensive intervention (involving an active
participation and collaboration between the patients, the health-
care providers, and the community) will tackle the above
mentioned weak points and challenges of the ART programme,
and help in retaining patients as long as possible on first line ARV
drugs available in the country [8]. Also, ensuring the availability of
standardized ART registers in every ART site (ATC or HMU) is
of great asset to the monitoring-evaluation process of the program
and its strength in minimizing the burden of drug resistant
patterns. During this study, we also observed a lack of regular
supervision. Therefore, increasing the frequency of on-site
supervision may also be of support in preventing HIVDR using
EWIs. The national strategy toward ART adherence may need to
be revised. Also, the role and positioning of community relay
agents would be of paramount importance in the identification of
lost to follow-up. In this prospect, improving communication
strategies on ART adherence is necessary. Lastly, an active
mentorship of HMU by an ATC is recommended, taking into
consideration the key role of ARV ‘‘treatment committee’’, as well as
the required skills for routine data collection, analysis and on-site
result exploitation of EWIs [5,17]. Provision for staff continuous
training could ensure rapid corrective measures, improve patient
management and thus optimize on-site and the national HIVDR
surveillance and prevention system.
In conclusion, the level of EWIs for HIVDR in Cameroon
during the year 2010 indicates major challenges faced by the
national ART programme in its effort to limit the spread of
HIVDR. Despite the good ARV prescribing practices, indicators
related to patient adherence and drug supply were very poor, thus
reflecting the important risks of emerging HIVDR. Reducing the
workload with task shifting, together with a better community
engagement and regular site supervision, are key components to
set-up efficient HIVDR preventive strategies.
Acknowledgments
We would like to thank Doctor Patrick Kombate-Noudjo of WHO-Afro,
for his technical support in the implementation of the activities related to
HIV drug resistance prevention in Cameroon during the year 2010.
We also appreciate the contribution of Doctor Charles Fokunang
Ntungwen of the Faculty of Medicine and Biomedical Sciences of the
University of Yaounde 1, for the manuscript revision.
Author Contributions
Conceived and designed the experiments: SCB JF ASN EK PM ZT GND
AFA VC PMN ENM JBEN. Performed the experiments: SCB JF ASN EK
PM ZT. Analyzed the data: SCB JF ZT ASN EK PM GND VC PMN.
Wrote the paper: JF SCB EK ASN. Reviewed the manuscript: PM ZT
GND AFA VC PMN ENM JBEN. Approved the final submitted version:
SCB JF ASN EK PM ZT GND AFA VC PMN ENM JBEN.
Table 3. Overall national ART performance for each EWI.
Early Warning Indicators Required target
Sites meeting the target
(%)
EWI1: Good ARV prescribing practices (Percentage of patients initiated on an appropriate first line
ARV drug regimens)
100% 90%
(36/40)
EWI2: Lost to follow-up (% patient lost to follow-up after 12 months of enrolment to ART) #20% 20%
(8/40)
EWI3: Retention on first line ART (% patient retained on first line ART after 12 month of ART) $70% 20%
(8/40)
EWI4: On-time drug pick-up (Percentage of on-time ARV drug pick-up by the patient) $90% 0%
(0/37)
EWI5: Drug supply continuity (Percentage of month without drug shutdown at the pharmacy) 100% 45%
(17/38)
doi:10.1371/journal.pone.0036777.t003
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